Portage Biotech Performance
| PRTGDelisted Stock | USD 6.08 0.54 9.75% |
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Portage Biotech are completely uncorrelated. Portage Biotech right now holds a risk of 0.0%. Please check Portage Biotech accumulation distribution and period momentum indicator , to decide if Portage Biotech will be following its historical price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Portage Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Portage Biotech is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
Portage |
Portage Biotech Relative Risk vs. Return Landscape
If you would invest 608.00 in Portage Biotech on November 7, 2025 and sell it today you would earn a total of 0.00 from holding Portage Biotech or generate 0.0% return on investment over 90 days. Portage Biotech is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Portage, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Portage Biotech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Portage Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Portage Biotech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Portage Biotech is now traded under the symbol ATON. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Portage Biotech is not yet fully synchronised with the market data | |
| Portage Biotech has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (6.77 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Portage Biotech currently holds about 21.18 M in cash with (5.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.25. | |
| Roughly 61.0% of the company outstanding shares are owned by corporate insiders |
Portage Biotech Fundamentals Growth
Portage Stock prices reflect investors' perceptions of the future prospects and financial health of Portage Biotech, and Portage Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Portage Stock performance.
| Return On Equity | -5.42 | |||
| Return On Asset | -0.93 | |||
| Current Valuation | 9.86 M | |||
| Shares Outstanding | 2.28 M | |||
| Price To Book | 9.34 X | |||
| EBITDA | (7.38 M) | |||
| Cash And Equivalents | 21.18 M | |||
| Cash Per Share | 1.25 X | |||
| Total Debt | 3.05 M | |||
| Book Value Per Share | (0.07) X | |||
| Cash Flow From Operations | (5.46 M) | |||
| Earnings Per Share | (5.72) X | |||
| Total Asset | 2.23 M | |||
| Retained Earnings | (245.45 M) | |||
About Portage Biotech Performance
By analyzing Portage Biotech's fundamental ratios, stakeholders can gain valuable insights into Portage Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Portage Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Portage Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. It also provides Nanolipogel co-formulation platform for delivery of DNA aptamers and certain aptamer-small molecule-based combination products and STING agonist platform, a proprietary immune priming and boosting technology, offers various ways to target immune stimulation towards the cancer, as well as to co-deliver various signals in a single product. Portage Biotech is traded on NASDAQ Exchange in the United States.Things to note about Portage Biotech performance evaluation
Checking the ongoing alerts about Portage Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Portage Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Portage Biotech is now traded under the symbol ATON. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Portage Biotech is not yet fully synchronised with the market data | |
| Portage Biotech has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (6.77 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Portage Biotech currently holds about 21.18 M in cash with (5.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.25. | |
| Roughly 61.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Portage Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Portage Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Portage Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Portage Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Portage Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Portage Biotech's stock. These opinions can provide insight into Portage Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in poverty. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Other Consideration for investing in Portage Stock
If you are still planning to invest in Portage Biotech check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Portage Biotech's history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |